Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-MAGE-A1 TCR-engineered T cells TSC-204-C0702

A preparation of autologous T lymphocytes that are engineered to express a T-cell receptor (TCR) specific for melanoma-associated antigen A1 (MAGE-A1) presented on human leukocyte antigen (HLA)-C*07:02, with potential immunomodulating and antineoplastic activities. Upon administration, the autologous anti-MAGE-A1 TCR-engineered T cells TSC-204-C0702 specifically recognize and bind to MAGE-A1 expressed on tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing MAGE-A1. MAGE-A1 is a tumor-associated antigen (TAA) overexpressed by a variety of cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous MAGE-A1-specific HLA-C07:02-restricted TCR-expressing T lymphocytes TSC-204-C0702
MAGE-A1-specific HLA-C07:02-restricted TCR-engineered T cells TSC-204-C0702
MAGE-A1-specific TCR transduced autologous T cells TSC-204-C0702
MAGE-A1-specific TCR-transduced autologous T cells TSC-204-C0702
T-cell receptor engineered T Cells TSC-204-C0702
Code name:TSC 204-C0702
TSC-204-C0702
TSC204-C0702
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search